FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
BioPharma Dive5d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Hemophilia News Today9d
Bleeding, blood clot-related events in US tied to acquired hemophilia
About 30% of people hospitalized due to acquired hemophilia have a bleeding event, while 17% have a blood clot-related ...
The American Journal of Managed Care6d
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Fitusiran offers a 90% reduction in bleeding rates for hemophilia A or B with less frequent dosing than existing options. Phase 3 ATLAS trials showed significant efficacy, with many participants ...
The Eagle-Tribune5d
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia ...
Hemophilia News Today2d
Hemophilia patients’ bone health screening rates low at US HTCs
Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...